Abstract
Chronic lymphocytic leukemia can evolve to an aggressive lymphoma—in most of the cases diffuse large B cells lymphoma, rarely Hodgkin lymphoma—and this complication is defined Richter syndrome (RS). Immunogenotypic features that characterize RS include unmutated IgHV status with high prevalence of IgHV4-39/D6-13/J5 sequence; deletion of chromosome 17p or 11q; activation of oncogenes as NOTCH1 and c-MYC; inactivation of onco-suppressors as TP53 and CDKN2A; high expression of CD38 in lymph-nodes. The prognosis of this condition is very poor: patients experience a rapid clinical deterioration with frequent therapeutic failure since the current options include suboptimal strategies as standard chemo-immunotherapy followed by hematopoietic stem cells transplantation or enrollment in clinical trials which investigate the efficacy of target drugs. Understanding the biology of such a heterogeneous condition is crucial to personalize the treatment and improve patient's survival.
| Original language | English |
|---|---|
| Pages (from-to) | 293-300 |
| Number of pages | 8 |
| Journal | Hematological Oncology |
| Volume | 41 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2023 |
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology
- Cancer Research
Keywords
- IgHV mutational status
- Richter syndrome
- chromosomal aberrations
- chronic lymphocytic leukemia
- onco-suppressors
- oncogenes
Fingerprint
Dive into the research topics of 'Richter transformation in Chronic Lymphocytic Leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver